Used in cancer research as a potent antimitotic agent, Dolastatin 15 inhibits tubulin polymerization, disrupting cell division in tumor cells. It has served as a lead compound for developing antibody-drug conjugates (ADCs), particularly in targeting hematologic malignancies and solid tumors. Due to its high cytotoxicity, it is primarily utilized in conjugated forms to enhance tumor specificity and reduce systemic toxicity. Preclinical studies show promise in melanoma, leukemia, and lymphoma models. Its role remains largely experimental, supporting the design of novel chemotherapeutics rather than direct clinical use.